North America Pet Longevity Market

Overview

The North America Pet Longevity Market was valued at USD 1.50 billion in 2025 and is projected to reach USD 19.67 billion by 2034, growing at a CAGR of 33.1% during the forecast period (2026–2034). The market growth is driven by rising pet healthcare spending, growing adoption of preventive veterinary care, increasing demand for pet supplements and age-management products, growing pet owner focus on extending healthy lifespan. The market is shifting from an informal, reactive approach to aging pet care toward structured, recurring senior-pet care programs, as canine longevity drug candidates progress through regulatory review and give veterinary practices and pet owners a clearer signal that lifespan- and healthspan-extension support may become a mainstream clinical service category rather than a niche offering. Regulatory milestones for emerging longevity therapeutics are a central catalyst for this market, with progress by North American biotechnology companies developing canine lifespan-extension drug candidates through the US Food and Drug Administration's conditional approval pathway creating a new service layer around screening, owner counseling, and monitoring for aging companion animals. By pet type, senior dogs represented the largest segment of the market in 2025, reflecting the fact that canine longevity drug innovation and geriatric mobility care have so far concentrated first on dogs, while approximately 44% of US pet dogs are now classified as senior or geriatric, creating a substantial and well-established consumer base for joint health, cognitive support, and anti-aging supplement products across the region.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Progress of Canine Longevity Drug Candidates Toward Regulatory Approval Emerging as a Transformational Trend

• Biotechnology companies developing lifespan-extension therapeutics for dogs are advancing through staged regulatory review processes designed specifically for veterinary drug candidates, creating a credible near-term pathway to market that did not exist for this category several years ago.
• Successive, staged regulatory clearances for a lead longevity drug candidate function as a running signal to the wider industry, with each milestone renewing veterinary and media attention even though full commercial approval and launch remain a distinct, later step in the process.
• Veterinary practices across North America are beginning to prepare senior-pet care infrastructure, including recurring wellness plans and diagnostic protocols, in anticipation of eventually incorporating longevity drug screening and monitoring into routine practice offerings.
• A US biotechnology company's senior dog lifespan-extension program received FDA acceptance for reasonable expectation of effectiveness in February 2025, followed by FDA acceptance of the Target Animal Safety section of its Expanded Conditional Approval application in January 2026, marking successive regulatory milestones toward what could become the first approved canine longevity drug.

KEY MARKET DRIVER

Aging Pet Population and Rising Willingness to Invest in Preventive Care Are the Key Driver

• North America's large and growing companion animal population is aging in line with improved veterinary care and nutrition over pets' lifetimes, steadily expanding the base of senior dogs and cats that require structured geriatric support.
• The United States alone is home to more than 90 million pet-owning households, combined with high per-pet supplement spending, strong direct-to-consumer e-commerce infrastructure, and a deeply entrenched preventive veterinary care culture that together sustain demand for longevity-focused products and services.
• Rising translation of human longevity biology research into companion animal applications, including NAD+ precursor compounds, urolithin A, spermidine, and senolytic formulas targeting cellular hallmarks of aging, is expanding the range of scientifically credible products available to pet owners.
• Government Initiative such as the United States FDA’s Animal and Veterinary Innovation Centers initiative supports research and development of innovative animal health products and veterinary interventions, strengthening access to preventive and advanced care for companion animals and supporting longer, healthier pet lifespans.

KEY MARKET OPPORTUNITY

Expansion of Subscription-Based Geriatric Care Plans Creates Significant Market Opportunity

• Subscription-style senior-pet care plans that bundle wellness exams, diagnostics, and care navigation into a predictable recurring fee offer North American veterinary practices a way to build steadier, more forecastable revenue than episodic, symptom-driven visits alone.
• Pet insurers across the region that build preventive and early-intervention coverage specifically around senior-pet care could differentiate their offerings in a competitive market while supporting exactly the kind of proactive care this market is built around.
• Genetic and diagnostic testing providers that can connect breed- and age-related risk markers to structured care plans are positioned to become an integral upstream layer of the senior-pet care ecosystem rather than a standalone testing service.
• In 2025, 7.6 million pets were insured across North America, reflecting an 8.5% increase from 7.03 million in 2024 and indicating growing pet owner adoption of recurring healthcare spending models.

North America Pet Longevity Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Service Type

Senior-Pet Care Plans held the largest market share in 2025, because recurring monitoring wellness exams, pain review, lab checks, dental monitoring, and mobility planning forms the core service base that owners need on an ongoing basis rather than through single-visit treatment. Growing pet longevity awareness and the increasing prevalence of age-related health conditions are further encouraging owners to adopt structured care plans. These services also provide continuous health tracking and early intervention, supporting sustained demand among aging pets.

Anti-Aging Drug Support Services are projected to grow at the fastest CAGR during the forecast period, as canine longevity drug candidates progress through regulatory review and create a new service layer around screening, owner counseling, and monitoring that did not previously exist as a distinct veterinary service category. Growing interest in extending healthy lifespan and managing age-related conditions is expected to further increase demand for these specialized services.

Service Type categories include

• Senior-Pet Care Plans (Dominating Segment)
• Anti-Aging Drug Support Services (Highest Growth Segment)
• Veterinary Longevity Clinics
• Preventive Diagnostics
• End-of-Life Care

Analysis by Product

Supplements held the largest market share in 2025, driven by strong North American consumer demand for joint health, cognitive support, and anti-aging products, supported by a well-established direct-to-consumer e-commerce infrastructure and a large, established base of senior dogs and cats already receiving daily supplementation. Growing awareness of preventive pet healthcare is encouraging owners to use supplements as part of routine wellness management. Increasing product availability across veterinary clinics, specialty pet stores, and online channels is also supporting continued adoption.

NAD+ Precursors are projected to grow at the fastest rate during the forecast period, as the rapid translation of human longevity biology research into companion animal applications introduces increasingly sophisticated, cellular-level formulations beyond traditional joint and cognitive support ingredients. Growing interest in cellular health, metabolic function, and healthy aging is expected to increase demand for NAD+ precursor-based supplements. Expanding research into their potential role in supporting age-related biological processes is also encouraging product development and veterinary interest.

Product categories include

• Supplements (Dominating Segment)
• NAD+ Precursors (Highest Growth Segment)
• Growth Factors

Analysis by Pet Type

Senior Dogs held the largest market share in 2025, because canine longevity drug innovation and geriatric mobility care have so far concentrated first on dogs, and dog-focused services and products can scale more readily through clinics, diagnostics, and insurer programs than comparable feline-specific offerings. The larger installed base of senior dogs receiving routine veterinary care also supports demand for ongoing longevity monitoring and preventive interventions. Growing owner spending on mobility, nutrition, diagnostics, and age-related disease management is further supporting the segment’s market position.

Senior Cats are projected to grow at the fastest CAGR during the forecast period, as North American veterinary practices increasingly extend geriatric care protocols and diagnostic screening originally developed for dogs into feline-specific programs, addressing a historically underserved area of senior-pet care. Growing awareness of age-related conditions in cats is encouraging earlier health screening and continuous monitoring. Increasing adoption of preventive nutrition, mobility support, and chronic disease management is also expected to strengthen demand for senior-cat longevity services.

Pet Type categories include

• Senior Dogs (Dominating Segment)
• Senior Cats (Highest Growth Segment)

Analysis by Distribution Channel

Veterinary Clinics held the largest market share in 2025, driven by the growing role of veterinarians in preventive screening, geriatric assessments, diagnostics, prescription therapies, and personalized longevity plans for aging pets. Veterinary clinics also provide trusted access to supplements, therapeutic products, and monitoring services, supporting repeated purchases and long-term care. Increasing awareness of preventive pet healthcare is further encouraging owners to discuss longevity-focused interventions during routine veterinary visits.

Online Channels are projected to grow at the fastest CAGR during the forecast period, supported by expanding direct-to-consumer availability of pet supplements, nutraceuticals, diagnostics, and personalized wellness products. Greater product variety, subscription-based purchasing, convenient home delivery, and increasing consumer familiarity with online pet healthcare are expected to accelerate adoption. Digital platforms also enable brands to provide recurring wellness programs and personalized recommendations, strengthening their role in the longevity market.

Distribution Channel categories include

• Veterinary Clinics (Dominating Segment)
• Online Channels (Highest Growth Segment)
• Specialty Pet Stores
• Other Channels

By Region

North America Pet Longevity Market Share 2025, by Country

North America

xx%

South America

xx%

Europe

xx%

Middle East Africa

xx%

Asia Pacific

xx%

The United States held the largest market share in 2025, supported by more than 90 million pet-owning households, high per-pet supplement spending, and a deeply entrenched preventive veterinary care culture. Approximately 44% of US pet dogs are now classified as senior or geriatric, creating a substantial and well-established consumer base for joint health, cognitive support, and anti-aging supplement products. The country's leading position is further reinforced by its concentration of longevity biotechnology companies pursuing FDA regulatory approval for canine lifespan-extension drug candidates, and by major pet care manufacturers investing in expanded, vertically integrated nutrition and healthcare manufacturing capacity.

Mexico is projected to grow at the fastest CAGR during the forecast period, as rising pet humanization trends and expanding middle-class pet ownership across the country create a rapidly growing addressable population for senior-pet care products and services, albeit from a smaller current base than the United States or Canada. Growing availability of North American pet longevity brands through cross-border e-commerce and expanding veterinary care infrastructure are expected to support continued above-average growth in the Mexican market throughout the forecast period.

Countries Covered

• United States (Largest Country Market)
• Canada
• Mexico (Fastest-Growing Country Market)

Market Share

The market is fragmented and still forming, with emerging longevity-focused manufacturers such as Loyal, Gallant, Animal Biosciences, Nutramax Laboratories Veterinary Sciences, Thorne Vet, Vitality Science, Austin and Kat, Only Natural Pet, Dr. Harvey's, and NaturVet developing products focused on healthy aging, senior-pet health, regenerative care, and longevity support. Established animal-health manufacturers, including Elanco Animal Health, Virbac, Vetoquinol, Ceva Santé Animale, and Boehringer Ingelheim Animal Health, strengthen the competitive landscape through veterinary pharmaceuticals, nutritional products, supplements, and therapies addressing age-related and chronic conditions in companion animals. Among these players, Loyal and Gallant have a more direct focus on extending healthy lifespan and supporting regenerative health, while supplement and nutrition manufacturers compete through preventive and healthy-aging formulations. Key success factors include recurring product use and veterinary engagement, credible clinical evidence supporting healthspan-focused interventions, regulatory progress for longevity therapeutics, and the ability to establish trusted distribution channels across North American pet owners and veterinary practices.

Key Players

• Loyal (US)
• Gallant (US)
• Animal Biosciences (US)
• Nutramax Laboratories Veterinary Sciences (US)
• Thorne Vet (US)
• Vitality Science (US)
• Austin and Kat (US)
• Only Natural Pet (US)
• Dr. Harvey's (US)
• NaturVet (US)
• Elanco Animal Health Incorporated (US)
• Virbac (France)
• Vetoquinol S.A. (France)
• Ceva Santé Animale (France)
• Boehringer Ingelheim Animal Health (Germany)

Recent Market Developments

• June 2025: Gallant raised USD 18 million in Series B financing, led by Digitalis Ventures, to advance its ready-to-use stem cell therapy toward conditional FDA approval.
• September 2025: Virbac partnered with the Senior Dog Veterinary Society to advance education, awareness, and science-backed mobility solutions for aging dogs, including its MOVOFLEX and URSOLYX products.
• February 2026: Loyal raised USD 100 million in Series C financing to advance LOY-002, its lead longevity drug for senior dogs, toward FDA approval after completing the safety and efficacy requirements for Expanded Conditional Approval.
• May 2026: Gallant reported promising pilot data for its canine osteoarthritis IV-delivered stem cell therapy and received FDA-CVM eligibility for the expanded conditional approval pathway, with conditional approval targeted for 2028.

Frequently Asked Questions

Key Questions Answered

Request a Sample

1

What are the key drivers of the North America Pet Longevity Market?

2

Which service type holds the largest market share?

3

Which product segment is growing the fastest?

4

Why are senior dogs the dominant pet type?

5

What is driving growth in senior-cat longevity care?

6

How are veterinary clinics shaping market growth?

7

What role do supplements play in pet longevity?

8

How are subscription-based geriatric care plans creating opportunities?

Why Choose IG Transformation

Speak to Analyst

Strong Industry Focus

Extensive Product Offerings

Customer Research Services

Robust Research Methodology

Comprehensive Reports

Latest Technological Developments

Value Chain Analysis

Potential Market Opportunities

Growth Dynamics

Quality Assurance

Post-sales Support

Regular Report Updates